The CodeBreaK100 study (clinical trial information: NCT03600883) revealed that the objective response rate (ORR) was 41% and 12% for sotorasib-treated KRAS G12C-mutated NSCLC and KRAS G12C-mutated CRC respectively (Li et al., 2022). Here, KRAS is linked to non-small cell lung carcinoma.